Mainz Biomed B.V.

NasdaqCM MYNZ

Mainz Biomed B.V. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending December 31, 2023: -146.17%

Mainz Biomed B.V. Return on Assets (ROA) is -146.17% for the Trailing 12 Months (TTM) ending December 31, 2023. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: MYNZ

Mainz Biomed B.V.

CEO	Mr. Guido Baechler
IPO Date	Nov. 5, 2021
Location	Germany
Headquarters	Robert Koch Strasse 50
Employees	65
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Key trends

Past 5 years